Senior Vice President, Scinovo, Platform Technology and Science,
Paul Trennery is currently Senior Vice President and Head of Scinovo, Platform Technology
and Science (PTS). In this role he leads a team of senior scientists that provide an
innovative scientific support model for the drug discovery organisations that collaborate with
GSK R&D, helping to drive up the probability of success for our external collaborations. In
addition, his team have responsibility for developing PTS's outsourcing strategy and the
placement and management of regulated non-clinical discovery and development work
delivered via our external contract suppliers worldwide.
Paul is a member of a number of external industry committees in the area of drug
development, chairing the Nonclinical Sciences and Biological Discovery Expert Network
(NaBDEN) within ABPI, and is an invited member for the Development Funding Pathway
Scheme for the Medical Research Centre.
From 1999-2008 Paul had global responsibility for non-clinical safety evaluation in GSK as
head of Safety Assessment in Preclinical Development. Prior to this he served as Director of
Drug Safety Assessment in the USA, where he was also an Assoc. Adjunct Professor in
Toxicology at the University of North Carolina. Prior to his employment at GlaxoSmithKline,
he worked at Roche. Dr. Trennery holds a BSc from the University of Wales, a PhD in
Biochemistry from the University of Birmingham (UK), and is a Fellow of the Royal College of
What should Big Pharma do to help fill the skills gap? ( 710KB)
- GSK has implemented a number of approaches including one that helps drug discovery
innovators build competencies in drug development by offering support.
- We are building stronger working networks with academia and SMEs, particularly now as
our internal discovery networks are being changed dramatically
- Two specific areas of focus where the right engagement could help build skills (i)
recognition of downstream risks, and (ii) knowing the key questions that need answering.
- People who can work at the interface of disciplines are important resources, including those
who know how to build collaborations.
- Investment into the external environment now better targeted to build value, rather than
offer broad financial support.